Medacta Group S.A. (0A05) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, this is the Coral School Conference Operator. Welcome and thank you for joining the Medacta Group Full Year 2024 Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Mr. Francesco Siccardi, CEO of Medacta Group. Please go ahead, sir. Thank you, and good afternoon, everybody. Welcome to Medacta 2024 full year results. I am here with Corrado Forsetta, MD, CFO, and we will guide you through the presentation we released this morning. First of all, let's just remember our disclaimers. So the highlights of 2024 started with our revenue release that we already published A few weeks ago, a very good growth, over 16% in cost and currency, surpassing €590 million. And this is combined with a good, excellent profitability with a 28% EBDA margin in cost and currency or 27.1 in euro, a good increase of 19.4% over 2023. The net profit as well increased by almost 54% to 73 million euro roughly. And we are proposing a dividend of 0.69 Swiss francs per share, which represents an increase of over 25% year over year. 2024 is now the fifth year of very, very strong growth. Between 2020 and 2024, the CAGR has been 18%, 18.1%. And this considerable above-market revenue growth is a result of our innovative products that have been developed and are able to often change the way things are done. The more innovation we put in the market, the more medical education is required to support the safe introduction of this innovation and safe adoption of this innovation by our customers. And we have....